C. Derdemezis

发表

Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship?

P. Voulgari, A. Drosos, D. Kiortsis, 2011, Clinical and experimental rheumatology.

Increased plasma visfatin levels in subjects with the metabolic syndrome

M. Elisaf, T. Filippatos, I. Gazi, 2007, European journal of clinical investigation.

Excess body weight and risk of first‐ever acute ischaemic non‐embolic stroke in elderly subjects

D. Mikhailidis, H. Milionis, J. Goudevenos, 2007, European journal of neurology.

The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

M. Elisaf, D. Mikhailidis, D. Mikhailidis, 2008, Expert opinion on pharmacotherapy.

Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study

M. Elisaf, D. Mikhailidis, C. Derdemezis, 2008 .

Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.

P. Voulgari, A. Drosos, T. Filippatos, 2010, Clinical and experimental rheumatology.

Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study

A. Drosos, V. Tsimihodimos, C. Derdemezis, 2013, Scandinavian journal of rheumatology.

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.

M. Elisaf, T. Filippatos, D. Mikhailidis, 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.

M. Elisaf, D. Mikhailidis, C. Derdemezis, 2008, Expert opinion on pharmacotherapy.

Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome

M. Elisaf, D. Kiortsis, A. Tselepis, 2007, Journal of endocrinological investigation.

Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors

T. Filippatos, C. Derdemezis, C. Derdemezis, 2009 .

Combination of fenofibrate with non-statin drug regimens.

T. Filippatos, A. Agouridis, C. Derdemezis, 2010, Current pharmaceutical design.